Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by <i>Mycobacterium avium</i> Complex (CONVERT). A Prospective, Open-Label, Randomized StudyDavid E. Griffith, Kevin Winthrop, Gina Eagle et al.|American Journal of Respiratory and Critical Care Medicine|2018Cited by 343
Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung DiseaseKenneth N. Olivier, Richard J. Wallace, David E. Griffith et al.|American Journal of Respiratory and Critical Care Medicine|2016Cited by 246
Contribution of Tissue Factor Associated with Factor VIISteven Idell, Robert W. Colman, Peter N. Walsh et al.|American Review of Respiratory Disease|1987Cited by 132
Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Lung DiseaseDavid E. Griffith, Kevin Winthrop, Rachel Thomson et al.|CHEST Journal|2021Cited by 52
Airway Clearance Techniques in BronchiectasisAshwin Basavaraj, Kevin Winthrop, Radmila Choate et al.|CHEST Journal|2020Cited by 47